 Shares of Lannett Company Inc. gained 0.2 after the company said it will cut 80 positions, about 8.5 of its total workforce, over concerns that its generic fluphenazine product will face competition from Amneal Pharmaceuticals Inc. , which last week received a Food and Drug Administration approval for a generic form of the antipsychotic. Amneal said last week that annual U.S. sales of fluphenazine in the U.S. are 143 million. LCIs dominance of the generic fluphenazine market, a key high margin driver and LCIs largest product in the wake of the loss of levothyroxine, ended yesterday with Amneals entrance, Raymond James analyst Elliot Wilbur told investors on Friday. Though competition was expected, it is always hoped to happen later rather than sooner. The job losses will be at Lannetts Seymour, Indiana plant. Consolidating research development in one location in Philadelphia is expected to save the company 15 million annually. Lannetts stock is down 34.9 year-to-date, while the SP; 500 has declined 1.4. 